Literature DB >> 19265662

PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.

Anne-Marie Bleau1, Dolores Hambardzumyan, Tatsuya Ozawa, Elena I Fomchenko, Jason T Huse, Cameron W Brennan, Eric C Holland.   

Abstract

In normal brain, the side population (SP) phenotype is generated by ABC transporter activity and identifies stem cell and endothelial cell subpopulations by dye exclusion. By drug efflux, the ABCG2 transporter provides chemoresistance in stem cells and contributes to the blood brain barrier (BBB) when active in endothelial cells. We investigated the SP phenotype of mouse and human gliomas. In glioma endothelial cells, ABC transporter function is impaired, corresponding to disruption of the BBB in these tumors. By contrast, the SP phenotype is increased in nonendothelial cells that form neurospheres and are highly tumorigenic. In this cell population, Akt, but not its downstream target mTOR, regulates ABCG2 activity, and loss of PTEN increases the SP. This Akt-induced ABCG2 activation results from its transport to the plasma membrane. Temozolomide, the standard treatment of gliomas, although not an ABCG2 substrate, increases the SP in glioma cells, especially in cells missing PTEN.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265662      PMCID: PMC3688060          DOI: 10.1016/j.stem.2009.01.007

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  28 in total

1.  Neural stem cells from mouse forebrain are contained in a population distinct from the 'side population'.

Authors:  Marc-André Mouthon; Pierre Fouchet; Céline Mathieu; Karine Sii-Felice; Olivier Etienne; Céline Silva Lages; François D Boussin
Journal:  J Neurochem       Date:  2006-08-21       Impact factor: 5.372

2.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

Review 3.  ABCG2: determining its relevance in clinical drug resistance.

Authors:  Robert W Robey; Orsolya Polgar; John Deeken; Kin Wah To; Susan E Bates
Journal:  Cancer Metastasis Rev       Date:  2007-03       Impact factor: 9.264

4.  PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo.

Authors:  Dolores Hambardzumyan; Oren J Becher; Marc K Rosenblum; Pier Paolo Pandolfi; Katia Manova-Todorova; Eric C Holland
Journal:  Genes Dev       Date:  2008-02-15       Impact factor: 11.361

Review 5.  Cancer stem cells and survival pathways.

Authors:  Dolores Hambardzumyan; Oren J Becher; Eric C Holland
Journal:  Cell Cycle       Date:  2008-03-19       Impact factor: 4.534

6.  Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance.

Authors:  Jiangbing Zhou; Julia Wulfkuhle; Hao Zhang; Peihua Gu; Yanqin Yang; Jianghong Deng; Joseph B Margolick; Lance A Liotta; Emanuel Petricoin; Ying Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

Review 7.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

8.  Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells.

Authors:  Maria M Ho; Alvin V Ng; Stephen Lam; Jaclyn Y Hung
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

9.  Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.

Authors:  Patrick McConville; Dolores Hambardzumyan; Jonathan B Moody; Wilbur R Leopold; Alicia R Kreger; Michael J Woolliscroft; Alnawaz Rehemtulla; Brian D Ross; Eric C Holland
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

10.  Methylation damage response in hematopoietic progenitor cells.

Authors:  Ida Casorelli; Elvira Pelosi; Mauro Biffoni; Anna Maria Cerio; Cesare Peschle; Ugo Testa; Margherita Bignami
Journal:  DNA Repair (Amst)       Date:  2007-05-15
View more
  344 in total

Review 1.  Potential therapeutic implications of cancer stem cells in glioblastoma.

Authors:  Lin Cheng; Shideng Bao; Jeremy N Rich
Journal:  Biochem Pharmacol       Date:  2010-05-10       Impact factor: 5.858

2.  Myelin-forming cell-specific cadherin-19 is a marker for minimally infiltrative glioblastoma stem-like cells.

Authors:  Michael Zorniak; Paul A Clark; John S Kuo
Journal:  J Neurosurg       Date:  2015-01       Impact factor: 5.115

3.  Evidence for label-retaining tumour-initiating cells in human glioblastoma.

Authors:  Loic P Deleyrolle; Angus Harding; Kathleen Cato; Florian A Siebzehnrubl; Maryam Rahman; Hassan Azari; Sarah Olson; Brian Gabrielli; Geoffrey Osborne; Angelo Vescovi; Brent A Reynolds
Journal:  Brain       Date:  2011-04-22       Impact factor: 13.501

4.  Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype.

Authors:  Kaijie He; Tong Xu; Amir Goldkorn
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

5.  Harnessing the DNA Dye-triggered Side Population Phenotype to Detect and Purify Cancer Stem Cells from Biological Samples.

Authors:  Maximilian Boesch; Elisabeth Hoflehner; Dominik Wolf; Guenther Gastl; Sieghart Sopper
Journal:  J Vis Exp       Date:  2017-05-10       Impact factor: 1.355

6.  Piperlongumine inhibits cancer stem cell properties and regulates multiple malignant phenotypes in oral cancer.

Authors:  Yin-Ju Chen; Chia-Chun Kuo; Lai-Lei Ting; Long-Sheng Lu; Ya-Ching Lu; Ann-Joy Cheng; Yun-Tien Lin; Chien-Ho Chen; Jo-Ting Tsai; Jeng-Fong Chiou
Journal:  Oncol Lett       Date:  2017-11-24       Impact factor: 2.967

7.  miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2.

Authors:  Lei Shi; Zhimin Wang; Guan Sun; Yi Wan; Jun Guo; Xingli Fu
Journal:  Neuromolecular Med       Date:  2014-04-29       Impact factor: 3.843

8.  Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.

Authors:  Elisa Carra; Federica Barbieri; Daniela Marubbi; Alessandra Pattarozzi; Roberto E Favoni; Tullio Florio; Antonio Daga
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

9.  Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.

Authors:  Daniela Meco; Tiziana Servidei; Giuseppe Lamorte; Elena Binda; Vincenzo Arena; Riccardo Riccardi
Journal:  Neuro Oncol       Date:  2014-02-12       Impact factor: 12.300

Review 10.  Mouse models of glioblastoma: lessons learned and questions to be answered.

Authors:  Loury Janbazian; Jason Karamchandani; Sunit Das
Journal:  J Neurooncol       Date:  2014-02-13       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.